CORRECTED: Par Pays $100M To Settle Suit Over Generic Heartburn Drug
Law360, Los Angeles (September 22, 2014, 5:10 PM EDT) -- Par Pharmaceutical Cos. has agreed to pay $100 million to Salix Pharmaceuticals Inc. unit Santarus Inc. and the University of Missouri to resolve claims Par's generic version of the heartburn drug Zegerid infringed the university's patents, according to a Monday filing with the Securities and Exchange Commission.
Santarus, which is the exclusive licensee of the patents, and the University of Missouri, the patent owner, sued Par in 2007 seeking to block its release of a generic Zegerid, and a district court initially ruled in Par's favor, finding that two patents governing the drug's absorption were invalidated by obviousness. In 2012, however,...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!